Back to Agenda
Session 7: Global Developments & Potential Impact to Co-Development Strategies
Session Chair(s)
Lakshman Ramamurthy, PHD
Head of Global Regulatory, Precision Medicine and Digital Health, GlaxoSmithKline, United States
Megan Doyle, JD, MPH
Associate Vice President, Assistant General Counsel - Diagnostics, Eli Lilly and Company, United States
This session will discuss new developments in regulation and marketing of companion diagnostics globally, and potential impact on global development strategies. Specifically, the session will share challenges and considerations for executing global co-development programs. The session will focus primarily on regions outside of the U.S. and Europe, though discussions may include global impact of the approach in these regions.
Learning Objective : - Understand emerging developments in companion diagnostics globally.
- Explain the considerations to assess when planning global co-development strategies.
Speaker(s)
Katherine Wang, LLM
Chief China Life Sciences Advisor, Ropes & Gray LLP, China
Speaker
Mandi Jacobson, LLM
Partner, Hogan Lovells, Australia
Speaker
Lucy Yin, MD
Head of Precision Medicine, China , AstraZeneca, China
Speaker
Have an account?